Your browser doesn't support javascript.
loading
MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy.
Villa, Alessandro; Epstein, Joel B; Yarom, Noam; Hong, Catherine; Fulop, Caroline; Bossi, Paolo; Elad, Sharon.
Afiliación
  • Villa A; Miami Cancer Institute, Baptist Health South Florida, Oral Medicine, Oral Oncology and Dentistry, Miami, FL, 33176, USA. Alessandro.Villa@baptisthealth.net.
  • Epstein JB; Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. Alessandro.Villa@baptisthealth.net.
  • Yarom N; CA City of Hope National Medical Center, Oral Medicine Services, Duarte, CA, USA.
  • Hong C; Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel.
  • Fulop C; The Maurice Gabriela Goldschleger School of Dental Medicine, Faculty of Health and Medical Sciences, Tel Aviv University, Tel Hashomer Tel Aviv, Israel.
  • Bossi P; Discipline of Orthodontics and Paediatric Dentistry, Faculty of Dentistry National University of Singapore, Singapore, Singapore.
  • Elad S; Division of Dentistry, The Ottawa Hospital, Ottawa, ON, Canada.
Support Care Cancer ; 32(8): 549, 2024 Jul 25.
Article en En | MEDLINE | ID: mdl-39048808
ABSTRACT

PURPOSE:

A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the management of oral complications of targeted therapy.

METHODS:

This CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. Targeted agents were identified using the National Cancer Institute's list of Food and Drug Administration approved targeted therapy drugs. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care.

RESULTS:

Oral toxicities secondary to targeted therapy include various mucosal conditions, gingival conditions, jawbone disease, dysesthesia, taste change, and dry mouth. For the purpose of this CPS, we focused on oral mucosal conditions, gingival conditions, taste change, and dysesthesia. The treatment of oral toxicities depends on the symptom severity. Topical steroids and immunomodulators are often used as first-line therapy for oral mucosal toxicities. Treatment approaches for oral dysesthesia and taste change primarily revolve around symptoms management. Typically, therapy protocols align with the therapeutic algorithms employed for other neuropathic pain conditions, incorporating topical pharmacological interventions to achieve relief. Other oral toxicity requires a more specific approach.

CONCLUSION:

Management of oral toxicities from targeted molecular therapies is designed to alleviate patient discomfort and optimize treatment outcomes. Collaboration between medical and oral health professionals is necessary for best management practices.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Molecular Dirigida / Enfermedades de la Boca / Antineoplásicos Límite: Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Molecular Dirigida / Enfermedades de la Boca / Antineoplásicos Límite: Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania